| scholarly article | Q13442814 |
| review article | Q7318358 |
| P50 | author | Hao Li | Q85595530 |
| P2093 | author name string | Xiao-Yan Liu | |
| Jing Ma | |||
| Zhen Zhang | |||
| Hou-Wen Lin | |||
| Yi-Hong Jiang | |||
| Long Shen | |||
| Zhi-Chun Gu | |||
| Yao-Min Hu | |||
| Fang-Hong Shi | |||
| P2860 | cites work | Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015 | Q27468570 |
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation | Q29615706 | ||
| Meta-Analysis of Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cardiovascular Outcomes and All-Cause Mortality Among Patients With Type 2 Diabetes Mellitus | Q30245104 | ||
| Effects of sodium-glucose co-transporter 2 (SGLT2) inhibition on renal function and albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis | Q32186373 | ||
| Osmotic diuresis with SGLT2 inhibition: analysis of events related to volume reduction in dapagliflozin clinical trials | Q33166813 | ||
| Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis | Q33767478 | ||
| Novel oral glucose-lowering drugs are associated with lower risk of all-cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes | Q33835709 | ||
| Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030. | Q51767622 | ||
| Lower Cardiovascular Risk Associated with SGLT-2i in >400,000 Patients: The CVD-REAL 2 Study. | Q52655573 | ||
| SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials. | Q54266015 | ||
| Clinical adverse effects of sodium-glucose cotransporter 2 inhibitors: Protocol for a systematic review and meta-analysis | Q58789064 | ||
| Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular disease, death and safety outcomes in type 2 diabetes - A systematic review | Q88233662 | ||
| SGLT2 inhibitors and the kidney: Effects and mechanisms | Q89125399 | ||
| Type 2 diabetes | Q89258111 | ||
| SGLT2 inhibition and kidney protection | Q89323836 | ||
| The actions of SGLT2 inhibitors on metabolism, renal function and blood pressure | Q91071799 | ||
| Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes | Q34673134 | ||
| Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. | Q35968414 | ||
| Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program | Q35973246 | ||
| Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition | Q35973255 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Diabetes and its comorbidities--where East meets West | Q38109814 | ||
| Genital and urinary tract infections in diabetes: impact of pharmacologically-induced glucosuria | Q38188185 | ||
| Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes | Q38729780 | ||
| Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: A network and cumulative meta-analysis of randomized controlled trials. | Q38940175 | ||
| Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections | Q39474763 | ||
| Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trials | Q40068172 | ||
| Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials | Q40445386 | ||
| Acute renal failure with sodium-glucose-cotransporter-2 inhibitors: Analysis of the FDA adverse event report system database | Q47366627 | ||
| Cardiovascular Safety, Long-Term Noncardiovascular Safety, and Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis With Trial Sequential Analysis | Q47652080 | ||
| Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias? | Q48374438 | ||
| Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. | Q48599312 | ||
| Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis. | Q49668043 | ||
| 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. | Q49988613 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | placebo | Q269829 |
| P304 | page(s) | 1066 | |
| P577 | publication date | 2019-09-19 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials | |
| P478 | volume | 10 |
| Q90043452 | Basic and Clinical Pharmaco-Therapeutics of SGLT2 Inhibitors: A Contemporary Update | cites work | P2860 |
Search more.